NY-TZ30

Each lot of NY-TZ30 30mg is characterized for identity and purity using analytical methods standard to peptide research:

• Purity: reversed-phase HPLC, with material released at ≥99% chromatographic purity.
• Identity: mass spectrometry (MS) to confirm the expected molecular mass of the peptide.
• Reference data: lot-specific values are reported on the accompanying COA.
• Certificate of Analysis: a lot-specific COA documenting the measured purity and identity accompanies each lot.

These analyses are analytical characterizations of identity and purity only. They are not a determination of safety or fitness for any in-vivo, diagnostic, or therapeutic application. For research use only, not for human use.

A Certificate of Analysis is available per production lot, documenting HPLC purity and mass-spectrometry identity confirmation.

View Certificates of Analysis →

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

References to clinical phases/studies describe the compound in independent third-party literature (e.g., ClinicalTrials.gov, PubMed) and do not represent claims, testing, or approval by NYsub Peptides.

NY-TZ30 is a synthetic peptide described in the scientific literature as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It belongs to the class of multi-receptor incretin-mimetic peptides whose molecular targets and receptor pharmacology have been investigated in peer-reviewed laboratory research.

This material is supplied solely as a research chemical for in-vitro and laboratory use. It has not been tested, validated, or approved by NYsub Peptides for any application, confers no approved status, and no claim is made regarding biological effect. For research use only, not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

In the published third-party literature, NY-TZ30 has been studied as a tool compound in laboratory and in-vitro research lines, including:

• Receptor pharmacology of the GIP and GLP-1 receptors — binding, activation, and biased/imbalanced signaling, as examined in cell-based assays.
• Receptor internalization and trafficking, as characterized in heterologous expression systems.
• Incretin and intracellular-signaling pathway studies (e.g., cAMP and downstream signaling) in cultured cell models.
• Structure–activity and peptide-chemistry research on dual-agonist peptide design.

These application areas are provided for scientific context only, based on third-party publications. This product is supplied for laboratory research and is not for human use, diagnostic use, or therapeutic use.

Store the lyophilized powder at -20°C, protected from light and moisture; lower temperatures may be used for extended storage per laboratory standard practice. Stability with bacteriostatic or sterile water has been characterized for laboratory reference only, under refrigerated storage with aliquoting to minimize freeze-thaw cycles. Handle with appropriate PPE. Not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

• General receptor-pharmacology literature describes GIP, GLP-1, and glucagon receptor signaling and multi-receptor (poly-agonist) peptide mechanisms in in-vitro models.
• Lot-specific analytical results (identity and purity) are documented on the accompanying Certificate of Analysis.

Supplied for laboratory research use only. Not for human use.